Forty Seven Inc.
1661 Page Mill Road
Suite C
Palo Alto
California
94304
United States
Tel: 650-352-4150
Website: http://www.fortyseveninc.com/
Email: info@fortyseveninc.com
About Forty Seven Inc.
Forty Seven Inc., a new biotechnology company specializing in cancer immunotherapy, is powering two upcoming anti-cancer studies with the Medidata Clinical Cloud®.
Forty Seven is named after the CD47 tumor cell protein that its lead molecule, Hu5F9-G4–an experimental monoclonal cancer drug–aims to attack. The biotech is embarking on a series of clinical trials to test its safety and efficacy in solid tumor and blood cancers. As part of these efforts, Forty Seven is using Rave in two of its upcoming Phase I and Phase II trials to streamline study operations, improve data quality and accessibility, and speed decision-making processes.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Jonathan MacQuitty, Ph.D., M.B.A.
Chief Business Officer: Craig Gibbs, PhD., M.B.A.
Chief Medical Officer: Chris Takimoto M.D. Ph.D.
Chief Patent Officer: Norm Kruse PhD., J.D
40 articles about Forty Seven Inc.
-
The FDA placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus azacitidine due to concerns of unexpected adverse events.
-
Gilead Completes Acquisition of Forty Seven, Inc.
4/7/2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead (“Purchaser”), to acquire Forty Seven, Inc. (Nasdaq: FTSV) for $95.50 per share, net to the seller in cash, without interest, or approximately $4.9 billion in the aggregate. On March 2, 2020, Gilead and Forty Seven announced that Forty S
-
Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
3/20/2020
Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.
-
Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia
3/11/2020
Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with Rocket’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy, RP-L102.
-
Gilead to Acquire Forty Seven for $4.9 Billion
3/2/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash.
-
“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chairman and chief executive officer.
-
Shares of Forty Seven Inc. were up in premarket trading on rumors that Gilead Sciences has approached the company about a potential partnership or acquisition.
-
Forty Seven to Present at Upcoming Investor Conferences in March 2020
2/25/2020
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, announced its participation in the following upcoming investor conferences
-
Forty Seven to Present at Upcoming Investor Conferences in February 2020
2/6/2020
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, announced its participation in the following upcoming investor conferences
-
Forty Seven Announces 2020 Strategic Priorities and Expected Milestones
1/10/2020
Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020
-
Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares
12/16/2019
Gross proceeds from the offering, before underwriting discounts and commissions and offering expenses, were approximately $195.6 million.
-
Clinical Catch-Up: December 9-13
12/16/2019
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look. -
Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock
12/12/2019
Forty Seven, Inc. announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 per share.
-
Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock
12/11/2019
Forty Seven, Inc., a clinical stage immuno-oncology company, announced that it has commenced an underwritten public offering of $140,000,000 of shares of its common stock.
-
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
-
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
12/9/2019
Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced the presentation of updated clinical data from its ongoing trial evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
-
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
12/9/2019
Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced preclinical proof-of-concept data for its novel all antibody conditioning regimen, comprised of FSI-174, its anti-cKIT antibody, and magrolimab, its anti-CD47 antibody.
-
bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy
11/12/2019
bluebird bio, Inc. and Forty Seven, Inc. announced that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 plus magrolimab, with bluebird’s ex vivo lentiviral vector hematopoietic stem cell gene therapy platform.
-
Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights
11/12/2019
Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin
-
Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual MeetingForty Seven to Host Investor Event and Webcast on December 9, 2019
11/6/2019
Forty Seven, Inc. announced that updated data from its ongoing Phase 1b study evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukemia, including additional efficacy and durability data from a larger number of patients, will be presented in an oral presentation at the 61st American Society of Hematology Annual Meeting, which is taking place Dec 7-10, 2019 in Orlando, Florida.